CARBOPLATIN - THE CLINICAL SPECTRUM TO DATE
CARBOPLATIN - THE CLINICAL SPECTRUM TO DATE
复制标题
DOI：
10.1016/0305-7372(85)90027-1
复制
发表时间：
1985-09-01
影响因子：
11.8
通讯作者：
CARTER, SK
中科院分区：
文献类型：
--
作者：
CANETTA, R;ROZENCWEIG, M;CARTER, SK
本文回顾了1985年6月以来有关卡铂的文献资料。该化合物似乎保留了与顺铂相同的活性谱，并且可获得一组明确的有效性数据，用于上皮来源的卵巢癌、肺小细胞癌和头颈部表皮样癌。尚未发表的关于卡铂的毒性数据表明，该化合物的治疗指数优于母体化合物顺铂，并且似乎不劣于目前临床试验中的另一种铂配位化合物异丙铂。
The existing literature data base on carboplatin updated to June, 1985 has been reviewed. The compound seems to retain the same spectrum of activity as cisplatin, and a definite set of efficacy data is available for ovarian cancer of epithelial origin, small cell carcinoma of the lung and epidermoid carcinoma of the head and neck. A yet unpublished toxicity data base on carboplatin suggests that the compound has an improved therapeutic index over the parent compound, cisplatin, and that it does not seem inferior to another platinum coordination compound currently in clinical trials, iproplatin.